BioTissue Holdings

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, BioTissue Holdings sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

BioTissue Holdings: 13 sponsored US clinical trials, none currently recruiting.

BioTissue Holdings sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 1 trials.

Top-decile sponsor footprint

BioTissue Holdings ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

COMPLETED Phase 2

A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.

NCT06780306
COMPLETED Phase 2

Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OA

NCT05079035
COMPLETED Phase 3

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT04450693
COMPLETED Phase 3

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

NCT04176120
COMPLETED Phase 2

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

NCT03818828
TERMINATED NA

FLO for Discogenic Pain

NCT03644251
TERMINATED NA

Management of Signs and Symptoms Associated With Dry Eye Disease

NCT04015219
COMPLETED Phase 2

Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)

NCT03230175
COMPLETED NA

Optimizing the Ocular Surface Prior to Cataract Surgery

NCT02766907
COMPLETED NA

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

NCT02707406
COMPLETED NA

In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye

NCT02764814
COMPLETED Phase 1

Demodex Blepharitis Treatment Study

NCT01647217
COMPLETED NA

Shunt Tube Exposure Prevention Study

NCT01551550

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 2

Therapeutic Areas

Dry Eye Disease 1

How the BioTissue Holdings early-phase archive is shaped

13 indexed studies, none listed as recruiting (0% open); 11 completed (85%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Dry Eye Disease (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

BioTissue Holdings: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

BioTissue Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share BioTissue HoldingsAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
BioTissue Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

BioTissue Holdings sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this BioTissue Holdings page

13 registered trials is a research-attention snapshot, not an endorsement of BioTissue Holdings or any single study.

  • None of BioTissue Holdings's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Dry Eye Disease is the condition BioTissue Holdings studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

BioTissue Holdings pipeline card: 13 registered trials from official public datasets.Report a data error.